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ABSTRACT
Read‑through transcripts result from the continuous transcription of adjacent, 
similarly oriented genes, with the splicing out of the intergenic region. They have 
been found in several neoplastic and normal tissues, but their pathophysiological 
significance is unclear. We used high‑throughput sequencing of cDNA fragments 
(RNA‑Seq) to identify read‑through transcripts in the non‑involved lung tissue of 64 
surgically treated lung adenocarcinoma patients. A total of 52 distinct read‑through 
species was identified, with 24 patients having at least one read‑through event, up to 
a maximum of 17 such transcripts in one patient. Sanger sequencing validated 28 of 
these transcripts and identified an additional 15, for a total of 43 distinct read‑through 
events involving 35 gene pairs. Expression levels of 10 validated read‑through 
transcripts were measured by quantitative PCR in pairs of matched non‑involved lung 
tissue and lung adenocarcinoma tissue from 45 patients. Higher expression levels 
were observed in normal lung tissue than in the tumor counterpart, with median 
relative quantification ratios between normal and tumor varying from 1.90 to 7.78; the 
difference was statistically significant (P < 0.001, Wilcoxon’s signed‑rank test for paired 
samples) for eight transcripts: ELAVL1–TIMM44, FAM162B–ZUFSP, IFNAR2–IL10RB,  
INMT–FAM188B, KIAA1841–C2orf74, NFATC3–PLA2G15, SIRPB1–SIRPD, and 
SHANK3–ACR. This report documents the presence of read‑through transcripts in 
apparently normal lung tissue, with inter‑individual differences in patterns and 
abundance. It also shows their down‑regulation in tumors, suggesting that these 
chimeric transcripts may function as tumor suppressors in lung tissue.
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INTRODUCTION
Several genetic alterations have been reported to 
act as driver events in lung tumorigenesis or to modulate 
the progression of lung tumors and their responses to 
therapy [1, 2]. Among these alterations, chromosomal 
rearrangements (e.g. translocations, inversions and 
insertions) affecting genes encoding receptor tyrosine 
kinases, such as ALK, ROS1 and RET, have been extensively 
studied [1, 3–9]. These rearrangements can give rise to gene 
fusions by juxtapositioning previously independent coding 
sequences; when these fused genes are transcribed, they 
produce chimeric transcripts.
Chimeric transcripts can also be generated in the 
absence of chromosomal rearrangements, as a result of the 
transcriptional “read through” of two adjacent, similarly 
oriented genes, with the splicing out of the intergenic 
region [10]. The identification of read‑through transcripts 
has been made easier by the possibility of transcriptome 
sequencing using next‑generation technologies [11]. 
Through this approach, read‑through transcripts have been 
observed in several tumor types, such as breast, prostate, 
gastric, and renal cancer [12–18]. Read‑through transcripts 
in cancer tissues may have tumorigenic potential, since 
their silencing in cancer cell lines reduces cell proliferation 
[13–15]. In lung cancer, evidence for read‑through 
transcripts is currently limited to our incidental discovery, 
during a gene expression study, of RNA chimeras 
formed by the intergenic transcription of the conjoined 
genes PPP3R1 and CNRIP1, in a few samples of lung 
adenocarcinoma and normal lung tissue [19].
Even though the presence of read‑through 
transcripts in normal, non‑neoplastic tissue is documented 
[10, 12, 18, 20–23], their physiological role is still unknown. 
Computational and experimental analyses suggested that 
chimeric transcripts, including read‑throughs, are translated, 
producing fusion proteins with altered properties, such as 
new intracellular localizations and new functions, through 
the novel combination of protein domains [20, 24]. The 
biological functions of fusion proteins encoded by some 
read‑through transcripts have been primarily investigated 
in cancer cell lines, in order to understand their role in 
tumorigenesis: indeed, the effects of read‑through transcript 
silencing on cell proliferation, colony formation, and ability 
to grow in an anchorage‑independent manner (soft agar 
assay) have been reported [13, 14, 17, 25]. It has also been 
suggested that untranslated read‑through transcripts regulate 
gene expression at the RNA level, as either non‑coding 
RNA or regulatory RNA [22].
In this study, we used RNA sequencing to search 
for additional read‑through transcripts in normal lung 
parenchyma from adenocarcinoma patients. Candidate 
transcripts were examined by PCR followed by Sanger 
sequencing of the read‑through fusion points, permitting 
the validation of 43 transcripts. Comparison of the 
expression levels of 10 of these read‑through transcripts 
in paired samples of non‑involved lung tissue and lung 
adenocarcinoma tissue revealed lower levels in tumor 
tissue than in the normal tissue counterpart.
RESULTS
Detection of read‑through fusion events
Paired‑end whole transcriptome sequencing 
(RNA‑Seq) was carried out on 64 samples of RNA from 
non‑involved lung tissue of 64 lung adenocarcinoma 
patients (Table 1). The RNA‑Seq data were analyzed to 
identify chimeric transcripts involving two adjacent genes 
on the same chromosome, in the same orientation. This 
criterion, together with the fact that the RNA samples were 
from apparently normal tissue, maximized the probability 
that the identified chimeric transcripts had been generated 
by transcriptional read‑through events, without genetic 
aberrations. Among the 64 samples analyzed, 24 had at 
least one read‑through transcript, up to a maximum of 
17 different read‑through transcripts observed in a single 
patient. Altogether we found 52 unique read‑through 
species involving 37 different pairs of adjacent genes 
(Table 2). In some cases, the read‑through events 
involved different exons of the same pair of genes. Most 
read‑through transcripts were found in only one or two 
patients, but eight were found in 3–10 patients.
Validation of the detected read‑through fusion 
events
To confirm the existence of the read‑through 
transcripts identified by RNA‑Seq, we carried out PCR, 
using primers to amplify the sequence spanning the 
junction, on cDNA from at least one patient in whom each 
transcript was identified. For four transcripts, PCR did 
not amplify any sequence so these were excluded from 
further analysis. For 17 transcripts, we obtained multiple 
amplicons of different sizes, while for the remaining 31 
transcripts we obtained a single amplicon, with 21 of them 
having the expected molecular weight. Sanger sequencing 
of the amplicons validated 28 transcripts as predicted 
by RNA‑Seq and excluded seven of them (Table 2). 
Moreover, for the remaining 13 transcripts, Sanger 
sequencing did not confirm the predicted fusion point, but 
instead identified one or two different splicing isoforms 
involving different exons of the same conjoined genes 
(Table 3). Hence this analysis validated 28 read‑through 
transcripts among the 52 discovered using RNA‑Seq and 
identified 15 additional read‑through transcripts by Sanger 
sequencing of PCR products, for a total of 43 read‑through 
events involving 35 pairs of genes.
Read‑through transcription most frequently 
involved the second‑to‑last exon of the first gene, i.e. the 
one before the 3′‑UTR (in 28 of 43 cases, ~65%), and 
the second exon of the second gene (in 30 cases, ~70%). 
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Sometimes, however, the read‑through event was more 
complex. For instance, in the CD59–C11orf91 transcript, 
a portion of an intragenic (intronic) region was included. 
Moreover, in two cases, incomplete exons were found: 
HARS2 exon 13 in HARS2–ZMAT2 and SEC31B exon 2 
in NDUFB8–SEC31B. The median intergenic distance, 
calculated as the number of base pairs between the end 
of the first parent gene locus and the start of the second 
parent gene locus, was 3,941 bp. For 10 gene pairs the 
intergenic distance was greater than 10 kb, whereas 
in seven cases it was less than 1 kb. Four validated 
read‑though transcripts originated from overlapping 
genes. Finally, 17 read‑through events maintained the 
original open reading frames of the two coding sequences 
that were joined (Tables 2 and 3).
Expression levels of read‑through transcripts 
in matched samples of non‑involved and lung 
adenocarcinoma tissue
The expression levels of the 43 validated 
read‑through transcripts in non‑involved lung tissue were 
generally low (not shown). To examine their expression 
levels in lung adenocarcinoma tissue, we focused on 10 
transcripts whose levels were among the more abundant 
and for which only a single amplicon was obtained at PCR 
in the validation step. These transcripts were: CHIA–PIFO, 
CTSC–RAB38, ELAVL1–TIMM44, FAM162B–ZUFSP, 
IFNAR2(exon 7)–IL10RB(exon 2), INMT–FAM188B, 
KIAA1841–C2orf74, NFATC3–PLA2G15, SHANK3–ACR, 
and SIRPB1–SIRPD. We measured, by quantitative PCR, 
the expression levels of these read‑through transcripts 
in up to 45 pairs of matched tissues of non‑tumor lung 
parenchyma and lung adenocarcinoma tissue. Not all 
transcripts were measurable in all pairs of samples, and 
we excluded from further analyses those pairs for which 
qPCR data were unreliable (i.e. cycle threshold standard 
deviation > 0.5) in at least one sample. In all cases the 
median fusion transcript level was higher in normal lung 
tissue than in the tumor counterpart, and the difference was 
significant in eight cases (Figure 1). The median relative 
quantification ratios between normal and tumor varied 
from 1.90 (IFNAR2–IL10RB) to 7.78 (SHANK3–ACR). 
In detail, the difference of expression was statistically 
significant for ELAVL1–TIMM44 (P = 1.0 × 10–5, n = 25), 
FAM162B–ZUFSP (P = 3.8 × 10–6, n = 19), IFNAR2–IL10RB 
(P = 1.5 × 10–5, n = 25), INMT–FAM188B (P = 5.7 × 10–7, 
n = 26), KIAA1841–C2orf74 (P = 3.0 × 10–5, n = 24), 
NFATC3–PLA2G15 (P = 1.9 × 10–4, n = 28), SIRPB1–SIRPD 
(P = 4.8 × 10–7, n = 23), and SHANK3–ACR (P = 1.9 × 10–7, 
n = 33; Wilcoxon’s signed‑rank test for paired samples; 
Figure 1)
To determine if the expression levels of these 10 
read‑through transcripts were affected by the patients’ 
clinical characteristics, we fitted a multivariate linear 
model, treating sex, smoking habit, and disease stage 
(stage I or stage > I) as covariates (Table 4). This analysis 
confirmed that the expression levels were significantly 
associated with the type of tissue (normal vs. tumor) for 
the eight fusion transcripts and also found a significant 
effect for a ninth, namely CHIA–PIFO (P = 0.0184). 
Read‑through transcript levels were not affected by 
smoking habit. FAM162B–ZUFSP read‑through levels 
were significantly associated with disease stage and sex 
(P = 0.0015 and P = 0.019, respectively), whereas those of 
NFATC3–PLA2G15 were associated with sex (P = 0.040). 
The expression levels of the other read‑through transcripts 
were not affected by sex or stage.
Table 1: Clinical characteristics of the 64 lung adenocarcinoma patients from whom total RNA 
from resected non‑tumor lung tissue was analyzed by RNA‑Seq and of 45 lung adenocarcinoma 
patients from whom total RNA from non‑tumor and tumor lung tissue was analyzed by qPCR 
(these 45 patients included 6 patients analyzed by RNA‑Seq)
RNA‑Seq qPCR
Sex, n (%)
Men 50 (78.1) 34 (75.6)
Women 14 (21.9) 11 (24.4)
Age at surgery, years, mean (SD) 63.8 (7.3) 62.6 (10.7)
Smoking status, n
Smoker 61 31
Non‑smoker 1 11
Missing 2 3
Stage, n
I 55 18
II 3 8
III or IV 5 13
Missing 1 6
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Table 2: Read-through transcripts identified by RNA-Seq analysis
Read‑through 
name1
Chr.2 First transcript 
(exon)3
Second transcript 
(exon)3
Intergenic 
region (bp)
N. 
patients4
PCR 
validated
Maintained 
frame
AGRP‑
ATP6V0D1
16 NM_001138 (3) NM_004691 (2) 1,334 1 Yes No
ARF3‑FKBP11 12 NM_001659 (4) NM_001143781 (4) 9,249 1 Different6 See Table 3
ARPC4‑TTLL3 3 NM_001024959 (5) NM_001025930 (2) 360 10 Yes No
CD59‑C11orf91 11 NM_203331 (4) NM_001166692 (2) NA5 2 Different6 See Table 3
CHIA‑PIFO 1 NM_021797 (8) NM_181643 (2) 25,722 1 Yes Yes
CTSC‑RAB38 11 NM_001814 (5) NM_022337 (2) 118,125 2 Yes Yes
NM_001814 (4) NM_022337 (2) 1 No ‑
CTSD‑IFITM10 11 NM_001909 (8) NM_001170820 (2) 2,161 3 Yes Yes
NM_001909 (7) NM_001170820 (2) 2 No ‑
ELAVL1‑
TIMM44
19 NM_001419 (4) NM_006351 (3) 14,658 2 Different6 See Table 3
FAM162B‑
ZUFSP
6 NM_001085480 (3) NM_145062 (2) 83,406 1 Yes No
FARSA‑SYCE2 19 NM_004461 (12) NM_001105578 (3) 3,203 1 Yes Yes
HARS2‑ZMAT2 5 NM_012208 (13) NM_144723 (2) NA5 1 Different6 See Table 3
HSD17B11‑
HSD17B13
4 NM_016245 (5) NM_178135 (2) 13,704 1 Different6 See Table 3
IFNAR2‑IL10RB 21 NM_207584 (7) NM_000628 (2) 683 1 Yes Yes
NM_207584 (7) NM_000628 (3) 1 Yes No
INMT‑FAM188B 7 NM_001199219 (2) NM_032222 (2) 13,815 4 Yes No
NM_001199219 (2) NM_032222 (3) 7 No ‑
NM_001199219 (3) NM_032222 (3) 1 No7 ‑
KIAA1841‑
C2orf74
2 NM_032506 (21) NM_001143960 (2) NA5 1 Yes No
LMAN2‑MXD3 5 NM_006816 (7) NM_001142935 (4) 18,805 1 Yes Yes
MBD1‑CFAP53 18 NM_001204139 (14) NM_145020 (2) 360 1 Yes No
MED22‑SURF6 9 NM_133640 (4) NM_006753 (2) 1,925 1 Yes No
MRPS17‑GBAS 7 NM_015969 (1) NM_001202469 (3) NA5 1 No7 ‑
NAA60‑CLUAP1 16 NM_001083601 (1) NM_015041 (2) 13,961 1 Different6 See Table 3
NDUFB8‑
SEC31B
10 NM_005004 (4) NM_015490 (2) NA5 1 Yes No
NFATC3‑
PLA2G15
16 NM_173165 (9) NM_012320 (2) 16,045 2 Yes Yes
NKX2‑1‑SFTA3 14 NM_001079668 (2) NM_001101341 (4) 2,568 5 Yes No
NM_001079668 (2) NM_001101341 (2) 2 Yes No
NM_001079668 (1) NM_001101341 (2) 1 Yes No
NM_001079668 (1) NM_001101341 (4) 3 Different6 See Table 3
NM_001079668 (1) NM_001101341 (3) 5 No ‑
PACSIN2‑
ARFGAP3
22 NM_001184970 (10) NM_001142293 (3) NA5 1 Yes No
NM_001184970 (10) NM_001142293 (4) 1 Different6 See Table 3
PIR‑FIGF X NM_001018109 (9) NM_004469 (2) 423 1 Yes No
PLEKHO2‑
ANKDD1A
15 NM_001195059 (2) NM_182703 (5) 43,895 1 Yes Yes
NM_001195059 (4) NM_182703 (5) 1 Different6 See Table 3
PPRC1‑NOLC1 10 NM_015062 (13) NM_004741 (4) 1,851 1 Different6 See Table 3
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Table 3: Read-through transcripts identified by Sanger sequencing of PCR amplicons
Read‑through name1 First transcript (exon)2 Second transcript (exon)2 Maintained frame
ARF3‑FKBP11
NM_001659 (4) NM_001143781 (2) No
NM_001659 (4) NM_001143781 (3) No
CD59‑C11orf91 NM_203331 (4)* NM_001166692 (2)* No
ELAVL1‑TIMM44 NM_001419 (4) NM_006351 (2) No
HARS2‑ZMAT2 NM_012208 (13)§ NM_144723 (2) No
HSD17B11‑HSD17B13 NM_016245 (6) NM_178135 (2) No
NAA60‑CLUAP1 NM_001083601 (2) NM_015041 (2) No
NKX2‑1‑SFTA3 NM_001079668 (1) NM_001101341 (2)§ No
PACSIN2‑ARFGAP3 NM_001184970 (10) NM_001142293 (2) No
PLEKHO2‑ANKDD1A
NM_001195059 (5) NM_182703 (4) Yes
NM_001195059 (5) NM_182703 (5) Yes
PPRC1‑NOLC1 NM_015062 (13) NM_004741 (2) No
SNTB2‑VPS4A NM_006750 (6) NM_013245 (2) Yes
SPECC1L‑ADORA2A NM_015330 (14) NM_000675 (3) Yes
TSTD1‑F11R NM_001113205 (1) NM_016946 (2) Yes
1Gene1‑Gene2 symbol.
2Exons joined by the read‑through event.
*A portion of intragenic region is included in the read‑through transcript.
§Incomplete exon.
SCNN1A‑
TNFRSF1A
12 NM_001159575 (12) NM_001065 (2) 4,729 2 Yes Yes
NM_001159575 (12) NM_001065 (3) 2 No ‑
NM_001159575 (13) NM_001065 (2) 1 No7 ‑
NM_001159575 (10) NM_001065 (2) 1 No ‑
NM_001159575 (9) NM_001065 (2) 1 No ‑
SFTPC‑BMP1 8 NM_003018 (3) NM_001199 (2) 257 2 Yes No
SHANK3‑ACR 22 NM_033517 (22) NM_001097 (2) 4,898 1 Yes Yes
SIRPB1‑SIRPD 20 NM_001083910 (2) NM_178460 (2) 4,678 1 Yes Yes
SNTB2‑VPS4A 16 NM_006750 (6) NM_013245 (3) 2,304 1 Different6 See Table 3
SPECC1L‑
ADORA2A
22 NM_015330 (13) NM_000675 (3) 139 1 Different6 See Table 3
TSTD1‑F11R 1 NM_001113205 (1) NM_016946 (3) 16,283 2 Different6 See Table 3
VAMP8‑VAMP5 2 NM_003761 (2) NM_006634 (2) 2,377 5 Yes Yes
ZDHHC1‑TPPP3 16 NM_013304 (10) NM_016140 (3) 884 1 Yes No
ZNF343‑SNRPB 20 NM_024325 (6) NM_198216 (2) 10,964 1 No7 ‑
1Gene1‑Gene2 symbol.
2Chr.: chromosome.
3Exons joined by the read‑through event.
4Number of patients in which the read‑through transcript was identified by bioinformatic analysis of RNA‑Seq data.
5NA: not available; there is no intergenic distance since genes are overlapping.
6Identification of different read‑through fusion points by Sanger‑sequencing (see Table 3).
7No sequence amplified at PCR.
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Figure 1: Relative quantification (RQ) of read-through transcripts, in pairs of matched non-involved and tumor tissue 
from lung adenocarcinoma patients, reveals that read-through transcripts were expressed at lower levels in tumor 
tissue (T) than in the normal counterpart (N); n = number of normal‑tumor tissue pairs examined. The line within each 
box represents the median RQ; upper and lower edges of each box are 75th and 25th percentiles, respectively; top and bottom whiskers 
indicate the greatest and least RQ values, respectively. ***P < 0.001, paired Wilcoxon’s signed‑rank test for paired samples.
DISCUSSION
In this study we searched for read‑through 
transcripts, expressed in the non‑involved lung tissue of 
64 lung adenocarcinoma patients, by RNA‑Seq analysis. 
We confirmed by Sanger sequencing 43 read‑through 
events, involving 35 pairs of conjoined genes. For 10 of 
these validated read‑through transcripts, quantitative PCR 
analyses in paired samples of non‑involved and tumor 
tissue revealed that nine were down‑regulated in lung 
adenocarcinoma tissue.
Considering the 35 gene pairs involved in 
read‑through events, 26 had already been reported in the 
literature [10, 12, 14, 21, 22, 26] or annotated in one 
or more of the NCBI (http://www.ncbi.nlm.nih.gov/
gene/), Ensembl (http://grch37.ensembl.org/index.html), 
ConjoinG (http://metasystems.riken.jp/conjoing/index), 
and UCSC (https://genome‑euro.ucsc.edu/cgi‑bin/hg 
Gateway?redirect=manual&source=genome.ucsc.edu) 
databases (Supplementary Table S1). In particular, for 16 
gene pairs, the exact read‑through fusion point identified in 
this study had already been described, and for six of them 
(INMT–FAM188B, MED22–SURF6, NDUFB8–SEC31B, 
SCNN1A–TNFRSF1A, SIRPB1–SIRPD, and SNTB2−
VPS4) the transcripts had already been detected in lung, as 
indicated by ConjoinG database. For an additional 10 gene 
pairs, the reported read‑through events involved different 
exons and generated different read‑through transcript 
isoforms. Because of the stringent selection criteria used to 
select chimeric transcripts (using FusionAnalyser software 
for RNA‑Seq data mining) in our study, it is possible that 
additional read‑through transcripts are present in normal 
lung tissue and deserve further investigation; indeed, by 
PCR amplification, besides the candidate read‑through 
transcripts undergoing validation, we detected additional 
read‑through isoforms.
Features of the read‑through events identified in 
this study are comparable with those reported for other 
read‑through transcripts in other tissues. In particular, the 
median intergenic distance of our read‑through fusion 
events (3,941 bp) is small in comparison to that for all 
gene pairs in the human genome (estimated as 48 kb 
[10] and 64 kb [12]); this pattern was already observed 
in earlier studies on conjoined genes, which reported 
intergenic distances of 8.5–10 kb [10, 12, 22]. This 
recurrent finding indicates that read‑through events occur 
more frequently between close genes. Also, the frequent 
involvement of the exon just before the 3′‑UTR of the first 
parent gene and of the second exon of the second gene in 
the read‑through fusion events has already been observed 
in other studies of read‑through events in different tissues 
[10, 22].
Almost half of the identified read‑through fusion 
events (~42%) respected the original open reading frame 
of the two coding sequences that were joined. This 
percentage is slightly higher than the 25% observed by 
Akiva et al. [10]. When the reading frame is maintained, 
it is possible that a bifunctional fusion protein, containing 
domains of both the original proteins, can be produced, 
as already demonstrated for TWE–PRIL and Kua–UEV1 
proteins [27, 28]. In other cases, when the read‑through 
event causes a frame shift, new proteins may be created 
with an intact part of the first parent protein fused to an 
alternative isoform of the second. Even when read‑through 
transcripts are not translated into protein, they may have a 
role in regulating the expression of the parent genes [10]. 
Oncotarget27895www.impactjournals.com/oncotarget
Further studies are needed to clarify whether the 
read‑through transcripts identified here are translated into 
proteins or exert a regulatory function in normal lung tissue.
Until now, read‑through transcripts were typically 
found to be expressed at higher levels in tumor tissue 
of different cancer types than in the normal tissue 
counterpart [13, 14, 17, 25], leading to the suggestion 
that read‑through events were involved in carcinogenesis 
and tumor cell growth. Here, we show that chimeric 
transcripts, produced by the transcriptional read‑through of 
two adjacent genes, are frequently present in normal lung 
tissue; a similar phenomenon has recently been observed 
in human prostate cells [18]. Interestingly, nine of the 
read‑through transcripts identified here were significantly 
down‑regulated in lung adenocarcinoma tissue.
Multivariate statistical modeling did not find any 
influence of smoking habit on the expression levels of the 
read‑through transcripts. Therefore, it is unlikely that these 
read‑through transcripts originate from some alteration in 
transcription caused in lung tissue by tobacco smoking. 
Also sex and tumor stage did not influence read‑through 
transcript levels, except for FAM162B–ZUFSP which 
had a significant association with both covariates and for 
NFATC3–PLA2G15 whose levels were associated with 
sex. These results suggest that sex and stage may play only 
a minor role, if any, in the mechanisms behind our finding 
of a down‑regulation of these read‑through transcript in 
lung adenocarcinoma tissue. Therefore, after excluding 
smoking habit, sex and stage as confounders, we speculate 
that the down‑regulation of these read‑through transcripts 
in tumor tissue may be involved in the pathogenetic 
mechanism of lung tumorigenesis.
For five of the nine significantly down‑regulated 
read‑through transcripts (CHIA–PIFO, IFNAR2–IL10RB, 
NFATC3–PLA2G15, SIRPB1–SIRPD, and SHANK3–ACR), 
the reading frames of the two parent genes were 
maintained, suggesting that a chimeric protein could 
be produced. It will be interesting to investigate the 
existence of such proteins in normal lung tissue and in 
tumor tissue, and to determine if they have any functional 
role in lung adenocarcinoma pathogenesis. For the other 
read‑through transcripts, where the reading frame was not 
conserved and a premature stop codon was introduced, 
it will be interesting to investigate a possible regulatory 
Table 4: Influence of clinical characteristics on read-through transcript levels in lung 
adenocarcinoma tissue versus non-involved lung tissue, determined by testing in a multivariate 
linear model, using disease stage, smoking habit and sex as covariates
Read‑through1 Variable/Covariate2 Coefficient estimate SE3 P4
CHIA-PIFO
Tissue −11.88 4.85 0.0184
ELAVL-TIMM44
Tissue −13.58 4.44 0.004
FAM162B-ZUFSP
Tissue −18.69 1.87 1.45 × 10–10
Sex −4.982 2.00 0.019
Stage 6.945 1.96 0.001
IFNAR2-IL10RB
Tissue −10.25 4.33 0.024
INMT-FAM188B
Tissue −20.33 3.65 2.43 × 10–6
KIAA1841-C2orf74
Tissue −16.50 3.76 1.22 × 10–4
NFATC3-PLA2G15
Tissue −15.23 4.40 0.001
Sex −11.23 5.28 0.040
SHANK3-ACR
Tissue −25.61 3.95 4.27 × 10–8
SIRPB1-SIRPD
Tissue −18.94 3.76 2.29 × 10–5
1Quantitative levels were rank‑transformed to improve the normality distribution of values.
2 Tumor tissue as compared to non‑involved tissue; males as compared to females; ever smoker as compared to never smoker; 
stage > I as compared to stage = I.
3SE, standard error.
4P values are reported only if P < 0.05; CTSC-RAB38 showed P > 0.05 for all variables.
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role in the expression of the protein encoded by the first 
parent gene. Indeed, it has been suggested that these 
kinds of read‑through events suppress the expression of 
the upstream gene through the nonsense‑mediated decay 
mechanism [10, 29].
In summary, this report documents the existence of 
read‑through transcripts in normal lung parenchyma that 
are down‑regulated in tumor tissues of adenocarcinoma 
patients. The possible functions of these read‑through 
transcripts and their role in lung tumorigenesis remain to 
be elucidated.
MATERIALS AND METHODS
Tissue and RNA samples
This study used tissue samples held in a biobank at 
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 
Italy. The samples consisted of lung adenocarcinoma 
and matched non‑involved (apparently normal) lung 
parenchyma excised from patients who underwent 
lobectomy for lung adenocarcinoma in the authors’ 
institutes. Methods for the collection of samples and 
associated clinical data have already been reported [19]. 
Collection of tissue samples and clinicopathological 
information from patients had been undertaken with ethical 
review board approval and informed consent in accordance 
with the tenets of the Declaration of Helsinki. Specifically, 
the study protocol was approved by the Committees for 
Ethics of the institutes involved in recruitment (Fondazione 
IRCCS Istituto Nazionale dei Tumori, San Giuseppe 
Hospital, IRCCS Fondazione Cà Granda Ospedale 
Maggiore Policlinico).
For this study, we used RNA from 103 samples 
of non‑involved lung tissue (64 for RNA‑Seq and 45, 
including 6 of those used for RNA‑Seq, for quantitative 
PCR) and 45 samples of lung adenocarcinoma. The RNA 
had been extracted for previous studies [19, 30–32]. The 
clinical characteristics of the corresponding 103 patients 
are reported in Table 1.
RNA-Seq and identification of read-through 
transcripts
RNA‑Seq was carried out for 64 samples of 
non‑involved lung tissue as previously described [19]. 
Qseq files, containing the raw sequencing data, were 
de‑indexed and converted to the Sanger FastQ file format. 
FastQ sequences were aligned to the human genome 
assembly (GRCh37/hg19 version) using TopHat v.1.2.0 
software [33]. The resulting Sequence Alignment/Map 
(SAM) files were quality‑tested using SAM‑Profiler 
software [34], and only those with high mean read quality 
(> 30 Phred) were analyzed with FusionAnalyser software 
[35]. Candidate chimeric events were considered all those 
detected by ≥ 10 independent reads with a mean read 
quality ≥ 25 and with at least 1 read mapping across 
the predicted exonic breakpoint. These events were 
further filtered according to their reciprocal mapping 
and strandness: only adjacent genes mapping to the same 
gDNA strand were considered as correct read‑through 
predictions and subsequently tested by Sanger sequencing.
Amplification and Sanger sequencing
cDNA was synthesized, from the 64 RNA samples 
(1 μg each) analyzed by RNA‑Seq, using the SuperScript 
VILO cDNA Synthesis Kit (Life Technologies, Foster 
City, CA, USA). To verify the existence of the identified 
read‑through transcripts in non‑involved lung tissue, we 
amplified the junction regions, using cDNA from at least 
one sample in which the transcripts were first identified 
by RNA‑Seq. PCR reactions were performed using 40 ng 
cDNA, 0.6 U AmpliTaq Gold DNA Polymerase (Life 
Technologies), 0.2 µM primers spanning the junction 
between transcripts (sequences available upon request), 
1.5 mM MgCl2, 0.1 mM dNTPs, in a final volume of 
25 µl. Amplified fragments were visualized on 4% agarose 
gels together with Φ × 174 DNA‑Hae III digest used 
as DNA molecular weight marker. Amplicons were 
Sanger‑sequenced at Eurofins MWG Operon (Ebersberg, 
Germany), to verify the sequence at the transcript fusion site.
Quantitative PCR
RNA (1 μg) from 45 pairs of non‑involved lung 
tissue and corresponding lung adenocarcinoma tissue 
was used to synthesize cDNA by reverse transcription 
using the Transcriptor First Strand cDNA Synthesis Kit 
(Roche, Basel, Switzerland). To measure expression of the 
read‑through transcripts in tissue pairs, we did quantitative 
PCR (qPCR) assays with 12.5 ng cDNA template diluted 
in RNase‑free water, 5 µl 2× Fast SYBR Green Master 
Mix (Life Technologies), and 0.3 µM primers (sequences 
available upon request; these primers differed from those 
used to validate read‑through fusion points, since qPCR 
amplicons must be relatively short, i.e. 70–100 bp, whereas 
PCR amplicons for Sanger sequencing need to be longer) 
in a final volume of 10 µl. The human hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) gene was used to 
normalize expression data. Reactions were run in duplicate 
using the QuantStudio 12K Flex or 7900 HT Fast real‑time 
PCR system (Life Technologies). We considered as 
unreliable, and thus excluded, qPCR data of those pairs 
in which either the non‑involved or tumor sample, or 
both, had a cycle threshold (Ct) standard deviation > 0.5. 
For this reason, a different number of analyzed pairs is 
reported for each read‑through transcript in Figure 1. RQ 
values for each read‑through transcript were calculated, 
with ExpressionSuite Software v1.0.4 (Life Technologies), 
with respect to the RQ of the same transcript measured in 
Oncotarget27897www.impactjournals.com/oncotarget
a calibrator sample, composed of a pool of cDNAs from 
normal lung tissue samples previously found by RNA‑Seq 
to be positive for the measured read‑through transcripts.
Statistical analyses
Differences in transcript expression levels between 
normal and tumor tissues were tested for significance 
using the non‑parametric Wilcoxon’s signed‑rank test 
for paired samples. The effects of clinical characteristics 
on transcript levels were tested for significance in a 
multivariate linear model on rank‑transformed data [36]. 
Both statistical tests were executed using the R graphical 
user interface “R Commander” [37].
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